

Interactive patient case discussions in neuroblastoma Immunotherapy

Chair

Jaume Mora, MD, PhD, Pediatric Cancer Center Barcelona, Sant Joan de Déu Children's Hospital, Barcelona, Spain

Faculty

Giuseppe Barone, MB Bchir, PhD, Great Ormond Street Hospital for Children, London, UK

Daniel Morgenstern, MB Bchir, PhD, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, ON, Canada

Release date: January 2, 2023

Expiration date: January 2, 2024

Estimated time to completion: 1.0 hour

**Available CME credits: 1 AMA PRA Category 1 Credit(s)[™] and ANCC credit;
1 European CME credit (ECMEC[®])**

Activity description

This educational activity consists of patient case presentations on current and emerging immunotherapeutic strategies for the management of relapsed/refractory high-risk neuroblastoma.

During the patient case presentations, leading experts will provide you with:

- An overview of high-risk neuroblastoma and the challenges facing healthcare professionals
- Updates on current and emerging therapeutic options available globally for high-risk neuroblastoma, including a review of relevant data from clinical trials
- A review of immunotherapies as a first-line treatment option for high-risk neuroblastoma
- Insights on how to prepare for the management of adverse reactions during the administration of immunotherapy
- Insights into the evolving treatment landscape across the spectrum of neuroblastoma

Target audience

This activity has been designed to meet the educational needs of oncologists, surgeons, radiologists, nurses, pharmacists, physician assistants, and other healthcare providers involved in the management and treatment of patients with high-risk neuroblastoma.

Educational objectives

After completing this activity, the participant should be better able to:

- **Recognize** unmet needs in patients with relapsed/refractory high-risk neuroblastoma
- **Discuss** the rationale for, and role of, immunotherapy in the treatment of high-risk neuroblastoma
- **Evaluate** the efficacy and safety profiles of anti-disialoganglioside 2 (GD2)-based immunotherapies and emerging immunotherapies for central nervous system (CNS)/leptomeningeal metastases
- **Implement** optimal plans for administration of anti-GD2-based immunotherapies and management of adverse reactions

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of *1 AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.

European Accreditation Council for Continuing Medical Education (EACCME)



This e-learning activity is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) with 1 European CME credit (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS - EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for this activity.

In order to claim credit, participants must complete the following procedures during the period January 2, 2023, through January 2, 2024:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Complete the expert presentations
3. Take the post-activity test and complete the evaluation
4. Select the relevant credits and download the certificate of CME credit

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty	Relationship identified with:
Jaume Mora	Speakers Bureau/Honoraria for non-CME: YmAbs Therapeutics Consultant/Advisory Board: YmAbs Therapeutics.
Giuseppe Barone	Speakers Bureau/Honoraria for non-CME: EUSA pharma (Educational symposium during SIOP 2021).
Daniel Morgenstern	Speakers Bureau/Honoraria for non-CME: Ology Medical Education; WedMD Global, Platform Q Health Education; HMP Global; Razyebio Inc; Consultant/Advisory Board: YmAbs Therapeutics; Clarity Pharmaceuticals; EUSA Pharma; Receipt of grants/research supports: BMS; Unpaid consultancy: Oncoheroes Biosciences.

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Y-mAbs Therapeutics, Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

Sarita Cappello, Ology Program Manager
info@ologyeducation.org, www.ologyeducation.org

Chantel Crowl, Program Manager
inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Policy on privacy and confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Media

Internet